BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20005793)

  • 1. Switching on epigenetic therapy.
    Karberg S
    Cell; 2009 Dec; 139(6):1029-31. PubMed ID: 20005793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
    Bar-Sela G; Jacobs KM; Gius D
    Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the epigenetic code of cancer for therapy.
    Smith LT; Otterson GA; Plass C
    Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
    Vaissière T; Sawan C; Herceg Z
    Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatin-remodelling mechanisms in cancer.
    Lafon-Hughes L; Di Tomaso MV; Méndez-Acuña L; Martínez-López W
    Mutat Res; 2008; 658(3):191-214. PubMed ID: 18403253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic marking and neuronal plasticity.
    Duman RS; Newton SS
    Biol Psychiatry; 2007 Jul; 62(1):1-3. PubMed ID: 17572174
    [No Abstract]   [Full Text] [Related]  

  • 11. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
    Lunke S; El-Osta A
    J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
    Conley BA; Wright JJ; Kummar S
    Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
    Murgo AJ
    Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin modifying agents - the cutting edge of anticancer therapy.
    Kwa FA; Balcerczyk A; Licciardi P; El-Osta A; Karagiannis TC
    Drug Discov Today; 2011 Jul; 16(13-14):543-7. PubMed ID: 21664485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: epigenesis.
    Waggoner D
    Semin Pediatr Neurol; 2007 Mar; 14(1):7-14. PubMed ID: 17331879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone acetylation and chromatin signature in stem cell identity and cancer.
    Shukla V; Vaissière T; Herceg Z
    Mutat Res; 2008 Jan; 637(1-2):1-15. PubMed ID: 17850830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.